Latest news
APAC Healthcare Weekly (August 9) – Hengrui, CSPC Pharma, Takeda Pharma, Otsuka, Alteogen - SmartkarmaSmartkarma · Sat, 08 Aug 2026 07:00:00 GMTAlteogen Signs Up to $365 Million Hybrozyme Licensing Deal for Subcutaneous Biologic - BioPharma APACBioPharma APAC · Fri, 07 Aug 2026 01:45:01 GMTKorea's Alteogen inks $365 M deal for development and commercialisation of Hybrozyme™-enabled subcutaneous biologic product - biospectrumasia.combiospectrumasia.com · Thu, 06 Aug 2026 12:06:10 GMTAlteogen Inks Licensing Pact with Global Pharma Company to Develop, Commercialize Subcutaneous Biologic - Contract PharmaContract Pharma · Wed, 05 Aug 2026 15:57:30 GMTBig pharma reshuffles split Korea biotech as assets race toward trials and sales - CHOSUNBIZ - ChosunbizChosunbiz · Wed, 05 Aug 2026 02:10:00 GMTAlteogen licenses SC platform to global pharma in $365 million deal - CHOSUNBIZ - ChosunbizChosunbiz · Tue, 04 Aug 2026 23:37:00 GMT